Table 1

 Characteristics of Crohn’s disease patients treated with Infliximab and their Crohn’s disease controls who never received Infliximab, including only matched variables

CharacteristicInfliximab treated patients (n = 404) (n (%))Control patients (n = 404) (n (%))
*Median (range).
AZA, azathioprine; 6-MP, 6-mercaptopurine; ISS, immunosuppressants.
Sex
    Males214 (53%)214 (53%)
    Females190 (47%)190 (47%)
Crohn’s disease site
    Ileum101 (25%)93 (23%)
    Ileum-colon169 (42%)175 (43%)
    Colon127 (31%)134 (33%)
    Other7 (2%)2 (1%)
Immunosuppressants213 (53%)218 (53%)
    AZA/6-MP203 (95%)211 (97%)
    Methotrexate10 (5%)7 (3%)
Duration of ISS (months)*36 (3–160)24 (2–120)
Patient’s age (y)*41 (13–82)40 (14–82)
Crohn’s disease duration (y)*10 (1–62)9 (1–34)
Follow up in each centre (months)48 (6–396)60 (6–384)